Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937618 | 0.82 | NOS3 (0.31) | — | |
| SCHEMBL1333879 | 0.79 | — | — | |
| SCHEMBL13229341 | 0.79 | TSHR (0.35) | — | |
| SCHEMBL4546364 | 0.76 | GABRA1 (0.31) | TRPV1 | |
| SCHEMBL23366793 | 0.76 | CYP19A1 (0.33) | TRPV1 | |
| SCHEMBL12735789 | 0.74 | GCGR (0.30) | — | |
| SCHEMBL2743000 | 0.74 | GLP1R (0.34) | — | |
| SCHEMBL18610682 | 0.74 | — | — | |
| SCHEMBL24835433 | 0.74 | TAAR1 (0.40) | — | |
| SCHEMBL24782376 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3867237-B1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-03 | — | — | US | disclosed |
| EP-4105216-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-7718648-B2 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| WO-2008082488-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1771450-B1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | TRPV1 3158/4885CCR1 434/4885CCR5 33/4885 |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | TRPV1 9/4885CCR1 178/4885CCR5 2475/4885 |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | TRPV1 4823/4885CCR1 1195/4885CCR5 221/4885 |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | TRPV1 3814/4885CCR1 2167/4885CCR5 544/4885 |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | TRPV1 4342/4885CCR1 3914/4885CCR5 3392/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TRPV1 4856/4885CCR1 1728/4885CCR5 3140/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TRPV1 4825/4885CCR1 2507/4885CCR5 3349/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | TRPV1 2960/4885CCR1 1787/4885CCR5 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.